News

Today’s cancer treatment options are not one-size-fits-all. But Genprex, a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based on a unique proprietary technology platform, is working on developing its initial drug candidate for NSCLC that would potentially benefit a large patient population who cannot currently benefit from approved therapies….

AUSTIN, Texas & CAMBRIDGE, Mass.— (July 1, 2019) — Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company, today provided an update on development of its lead drug candidate, Oncoprex™ immunogene therapy, in combination with immunotherapy for the treatment of non-small cell lung cancer (NSCLC). 

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced it will be
presenting at the upcoming Sachs 5th Annual Immuno-Oncology BD&L and
Investment Forum at the Waldorf Astoria Chicago on May 31, 2019.

Earlier this month, Genprex’s President and Chief Operating Officer, Julien Pham attended the American Society of Gene & Cell Therapy’s 22ndAnnual Meeting in Washington, D.C., which brings together industry professionals committed to advancing knowledge, awareness and education of gene and cell therapy.

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced that it has taken a significant step toward commercialization of its lead drug candidate by retaining the services of leading pharmaceutical branding agency, Addison Whitney.

Gene therapy is a big and trending topic in the world of medicine and has recently been making headlines as large pharmaceutical companies have been ramping up acquisitions of gene therapy companies.

TUSC2 Immunogene Therapy Overcomes Resistance to Checkpoint Blockade

AUSTIN, Texas & CAMBRIDGE, Mass.— (April 8, 2019) — Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, reported that its collaborators from The University of Texas MD Anderson Cancer Center (“MD Anderson”) presented positive preclinical data for the combination of the TUSC2 gene with an anti-PD1 antibody, pembrolizumab, for the treatment of lung cancer in a poster presented at the American Association of Cancer Research Meeting 2019….

AUSTIN, Texas & CAMBRIDGE, Mass.— (April 1, 2019) — Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced a clinical and corporate update and the filing of financial results for the year ended December 31, 2018 on Form 10-K with the United States Securities and Exchange Commission….

Thermo Fisher recently announced it is buying Brammer Bio, which provides viral vector manufacturing services for gene and cell therapy companies. This acquisition is one of the many we have seen recently, as several other large pharmaceutical companies have been acquiring emerging gene and cell therapy companies with promising drug pipelines or drug approvals, including Roche’s acquisition of Spark Therapeutics, Biogen’s buying of Nightstar Therapeutics and Pfizer’s purchase of Vivet Therapeutics….

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced it will be presenting at the upcoming Cell &